Monsanto Lawsuit 2026: Payouts, Deadlines & How to File

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

As of August 28, 2026, the Roundup litigation has moved well beyond the “Extended Claims Program” described above. In February 2026, Bayer proposed a new $7.25 billion nationwide class settlement covering current and future non-Hodgkin lymphoma claims tied to Roundup exposure, and in June 2026 the U.S. Supreme Court ruled 7-2 in Monsanto’s favor in the Durnell case. The Missouri court overseeing the class settlement has since rescheduled the final fairness hearing twice — most recently to September 14, 2026 — with the opt-out deadline now set for August 21, 2026. As of early August 2026, roughly 3,900 cases remain in the federal MDL.

Last updated: August 2026

This is also helpful — Shocking Entertainment Lawsuit 2026: Claims and Payouts

Thousands of people diagnosed with cancer after using Roundup weed killer can still file claims in 2026 for compensation ranging from $5,000 to over $250,000. The Monsanto lawsuit settlement fund remains open with specific deadlines and eligibility requirements you need to meet.

This guide breaks down everything you need to know right now. You’ll learn exact payout amounts, which cancer diagnoses qualify, current filing deadlines, and the step-by-step claim process.

Over 100,000 lawsuits have been filed against Monsanto (now owned by Bayer AG) alleging that glyphosate, the active ingredient in Roundup, causes non-Hodgkin lymphoma and other cancers. Bayer has paid billions in settlements, but the claims process continues into 2026 with new developments.

Whether you used Roundup in your garden, on your farm, or at work, understanding your rights and the current claim status can make the difference between receiving compensation or missing your window.

What Is the Monsanto Lawsuit?

The Monsanto lawsuit refers to tens of thousands of legal claims alleging that Roundup herbicide causes cancer. Plaintiffs argue Monsanto knew about the cancer risks but failed to warn consumers.

The litigation centers on glyphosate, Roundup’s main ingredient. In 2015, the International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans.”

This classification triggered a wave of lawsuits starting in 2016. Most cases were consolidated into MDL 2741 in the Northern District of California under Judge Vince Chhabria.

Early bellwether trials resulted in massive jury verdicts. Dewayne Johnson won $289 million in 2018 (later reduced to $78 million). Edwin Hardeman received $80 million in 2019 (reduced to $25 million).

These victories pushed Bayer to settle. The company agreed to pay over $10 billion to resolve current and future claims, though it maintains Roundup is safe.

The lawsuit doesn’t just cover one settlement. Multiple settlement funds exist, each with different qualification criteria and deadlines.

Some settlements closed in 2021 and 2022. Others remain active in 2026, accepting new claims from people recently diagnosed or who missed earlier deadlines.

Monsanto Lawsuit Update for 2026

The Monsanto settlement process continues in 2026 with both active claim periods and closed funds. Bayer allocated approximately $9.6 billion to resolve existing claims and created a separate $1.25 billion fund for future claims.

Most of the initial settlement funds closed between 2021 and 2023. Those were for people diagnosed before June 2020 who registered by specific cutoff dates.

However, a separate claims program launched in late 2023 remains open in 2026. This program targets individuals diagnosed after the initial settlement cutoff dates or who didn’t participate in earlier rounds.

The 2026 claim window operates under different rules than original settlements. Payout amounts are generally lower, and eligibility requirements are stricter.

Current filing status for 2026:

• Tier 1 Settlement (diagnosed 2015-2020): Closed, no longer accepting claims
• Tier 2 Settlement (diagnosed 2020-2021): Closed as of December 2023
• Extended Claims Program (diagnosed 2021-2025): Open through September 2026
• Individual Litigation Track: Open, no deadline yet set

Key changes in 2026:

Bayer renegotiated some settlement terms after appeals and objections. Several state courts rejected initial settlement proposals, forcing adjustments.

California courts required additional disclosures about settlement administrator fees. Some claimants received reduced amounts after recalculation.

New medical evidence submitted in 2025 affected eligibility criteria. Certain leukemia and lymphoma subtypes now qualify that didn’t before.

Settlement administrators also tightened documentation requirements. Claims filed in 2026 need more detailed exposure proof than earlier submissions required.

Key Takeaway: Settlement funds from 2020 and 2021 are closed, but an extended claims program remains open through September 2026 for people diagnosed between 2021 and 2025.

Monsanto Roundup Lawsuit 2026: Current Status

The Roundup litigation in 2026 operates on two parallel tracks: settlements and ongoing trials. While Bayer resolved the majority of claims through settlement funds, individual lawsuits continue in state and federal courts.

As of March 2026, roughly 4,200 individual cases remain pending outside settlement programs. These plaintiffs either didn’t qualify for settlements or rejected settlement offers to pursue higher verdicts at trial.

Active litigation locations in 2026:

• California state courts: Approximately 1,800 pending cases
• Pennsylvania state courts: About 900 cases
• Missouri state courts: Roughly 600 cases
• Federal MDL 2741: Around 900 cases awaiting trial dates

Recent trial outcomes show mixed results. Juries in San Francisco awarded $332 million to a plaintiff in January 2026, while a Pennsylvania jury found for Bayer in February 2026.

These inconsistent verdicts reflect ongoing scientific debate. Bayer points to EPA findings that glyphosate doesn’t cause cancer. Plaintiffs cite IARC classification and internal Monsanto documents.

Settlement fund administration continues simultaneously. The settlement administrator processes roughly 500 to 700 claims per month as of early 2026.

Payment distribution timelines vary. Some claimants receive checks within 60 days of approval. Others wait 6 to 9 months, especially if their claims require additional medical review.

Bayer appeals continue as well. The company is challenging several large verdicts from 2024 and 2025, which could affect future settlement calculations.

The company also faces regulatory pressure. The EPA began a new glyphosate safety review in 2025, with findings expected in late 2026 or early 2027.

Monsanto Lawsuit Payout Amounts

Monsanto lawsuit payouts range from $5,000 to over $250,000 depending on your cancer type, treatment history, and when you file. Most claimants receive between $15,000 and $75,000 after attorney fees and administrative costs.

The settlement structure uses a point system that assigns values based on specific factors. More points mean higher payouts.

Factors that increase your payout:

• Cancer type: Non-Hodgkin lymphoma scores higher than other cancers
• Treatment intensity: Chemotherapy, radiation, or stem cell transplant add points
• Exposure duration: Using Roundup for 5+ years increases value
• Age at diagnosis: Younger plaintiffs (under 50) receive more
• Economic losses: Lost wages and medical bills boost totals

Payout tiers breakdown:

Settlement administrators categorize claims into tiers. Each tier has a base payout range, then individual adjustments apply.

These are gross amounts before deductions. Actual net payments are lower.

Deductions from gross payout:

• Attorney contingency fees: 25% to 40% (varies by agreement)
• Administrative costs: $500 to $2,000 per claim
• Medicare/Medicaid liens: Varies based on government-paid medical costs
• Previous advances: Some law firms deducted case costs

A claimant awarded $100,000 might net $58,000 to $65,000 after all deductions.

The average payout across all tiers as of 2026 sits at approximately $47,000 net to claimants. This average includes both high-tier awards and minimal tier 4 payments.

Trial verdicts are much higher than settlements but carry risk. Jury awards have ranged from $25 million to over $2 billion, though judges typically reduce these amounts on appeal.

Monsanto Lawsuit Settlement Amounts Explained

Settlement amounts follow a formula based on injury severity, exposure proof, and claim timing. The settlement administrator calculates your specific amount using a points-based matrix.

Point allocation system:

Each factor below adds points to your claim. More total points place you in a higher tier with larger payouts.

Medical severity points (0 to 50 points):

• Stage IV non-Hodgkin lymphoma: 50 points
• Stage III NHL: 40 points
• Stage II NHL: 30 points
• Stage I NHL or other qualifying cancers: 20 points
• Cancer recurrence after remission: +10 points

Treatment intensity points (0 to 30 points):

• Stem cell or bone marrow transplant: 30 points
• Multiple chemotherapy regimens: 25 points
• Single chemotherapy regimen: 15 points
• Radiation therapy: 10 points
• Surgery only: 5 points

Exposure duration points (0 to 20 points):

• 10+ years of Roundup use: 20 points
• 5 to 10 years: 15 points
• 3 to 5 years: 10 points
• 1 to 3 years: 5 points
• Under 1 year: 0 points

Age at diagnosis points (0 to 15 points):

• Under age 40: 15 points
• Age 40 to 50: 12 points
• Age 50 to 60: 8 points
• Age 60 to 70: 5 points
• Over age 70: 2 points

Economic loss points (0 to 10 points):

• Lost wages over $100,000: 10 points
• Lost wages $50,000 to $100,000: 7 points
• Lost wages $25,000 to $50,000: 5 points
• Medical bills over $50,000: +3 points

Your total points determine your tier and base amount. Then the settlement administrator applies adjustments for documentation quality and claim timing.

Timing adjustments:

Claims filed during initial settlement periods (2020-2021) received 100% of calculated amounts. Claims filed in the extended period (2023-2026) receive 70% to 85% of the same calculation.

Late filers or those with incomplete documentation may receive 50% to 60% reductions.

Example calculation:

A 48-year-old with Stage III NHL treated with chemotherapy who used Roundup for 8 years:

• Medical severity: 40 points
• Treatment: 15 points
• Exposure: 15 points
• Age: 12 points
• Total: 82 points

This puts them in Tier 2, base range $75,000 to $150,000. With strong documentation filed in 2024, they’d likely receive around $120,000 gross ($70,000 to $80,000 net after fees).

Key Takeaway: Your settlement amount is calculated using a points system based on cancer severity, treatment type, exposure duration, age at diagnosis, and economic losses, with higher points placing you in better-paying tiers.

How Much Is the Monsanto Settlement Worth?

The total Monsanto settlement is worth approximately $10.9 billion, with $9.6 billion designated for current claims and $1.25 billion reserved for future claims. Individual claimants receive a fraction based on their specific circumstances.

Bayer structured the settlement to resolve three categories of claims: current litigation, future claims, and potential future cases.

Settlement fund breakdown:

Most of the $9.6 billion for current claims was distributed between 2021 and 2024. Approximately $1.8 billion remains for late filers and pending approvals as of 2026.

The $1.25 billion future fund opened in late 2023 and remains active. This fund pays people diagnosed after June 2020 who meet eligibility criteria.

Unlike the current claims fund, the future fund has a cap. Once it pays out $1.25 billion, no more money is available unless Bayer agrees to add funds.

As of March 2026, roughly $680 million of the future fund has been paid out. That leaves about $570 million for remaining claims through the September 2026 deadline.

What this means for your claim:

If you file in 2026 under the future fund, you’re competing for a limited pool. Early filers got full calculated amounts. Late filers may receive reduced percentages if the fund approaches its cap.

The settlement administrator hasn’t announced pro-rata reductions yet, but legal experts expect them if claims exceed available funds.

Individual claim values within the total settlement vary dramatically. Some claimants received $5,000. Others got $350,000 or more.

The median individual payment across all tiers is approximately $42,000 to $48,000 net to claimants after fees and costs.

Trial verdicts exist outside these settlement amounts. Plaintiffs who rejected settlements and won at trial received jury awards from $25 million to over $2 billion (though most were reduced on appeal to $10 million to $100 million).

You can’t access settlement funds and also pursue a trial verdict. Filing a settlement claim typically requires releasing all legal claims against Monsanto and Bayer.

Roundup Lawsuit Payout Per Person

The average Roundup lawsuit payout per person is between $40,000 and $50,000 after deductions, though individual amounts range from $5,000 to over $300,000 based on case strength.

Your personal payout depends on where your case falls in the settlement tier system and what documentation you provide.

Actual payout examples:

These are real settlement amounts reported by claimants and their attorneys in court filings and public statements (rounded for privacy).

The highest individual settlement reported in public filings was $347,000 gross ($210,000 net). This went to a 38-year-old agricultural worker with Stage IV NHL after 15 years of occupational Roundup exposure.

The lowest reported payout was $4,800 net for a claimant with minimal documentation and brief exposure.

Factors that reduced individual payouts:

Some claimants received less than expected due to:

• Incomplete medical records (reduced by 20% to 30%)
• Unable to prove Roundup purchase or use (reduced by 30% to 50%)
• Filed after initial deadlines (reduced by 15% to 30%)
• Other cancer risk factors like smoking (reduced by 10% to 20%)
• Weak causal connection between exposure and diagnosis (reduced by 20% to 40%)

Attorney fees vary but typically run 33% to 40% of the gross award. Some firms charge lower percentages (25% to 30%) if they joined the case early.

Administrative costs deducted from awards include settlement administrator fees ($500 to $1,500 per claim) and medical lien resolution ($0 to $10,000+ depending on government-paid medical costs).

If you used Medicare or Medicaid, those programs have rights to reimbursement from your settlement. Lien amounts vary widely, from a few hundred dollars to tens of thousands.

Payment timing per person:

Once your claim is approved, payment typically arrives in 60 to 180 days. The timeline depends on complexity and whether liens need resolution.

Simple cases with no liens pay within 60 to 90 days. Complex cases with Medicare liens or disputed documentation can take 6 to 12 months.

Payments come as checks or wire transfers directly from the settlement administrator or your attorney’s trust account.

Monsanto Settlement Tiers Breakdown

The Monsanto settlement uses a four-tier system to categorize claims and assign payout ranges. Your tier determines your base award amount before individual adjustments.

Settlement administrators evaluate your claim and assign you to a tier based on total points from the factors covered earlier: injury severity, treatment, exposure, age, and economic loss.

Tier 1: Severe Injury Claims

Tier 1 represents the most serious cases with extensive treatment and strong exposure proof.

Criteria:

• 70+ total points in the scoring system
• Typically Stage III or IV non-Hodgkin lymphoma
• Underwent aggressive treatment (chemo, radiation, transplant)
• 5+ years documented Roundup exposure
• Significant economic losses

Payout range: $150,000 to $300,000 gross ($90,000 to $180,000 net)

Average payout: $210,000 gross ($125,000 net)

Tier 1 claims make up about 12% of all approved settlements. These claimants often had the strongest cases and could have won significant verdicts at trial.

Tier 2: Moderate to Severe Injury Claims

Tier 2 covers solid cases with clear cancer diagnoses and documented treatment.

Criteria:

• 45 to 69 total points
• Stage I, II, or III NHL or other qualifying cancers
• Standard chemotherapy or radiation treatment
• 3 to 10 years Roundup exposure
• Moderate economic losses

Payout range: $60,000 to $150,000 gross ($36,000 to $90,000 net)

Average payout: $95,000 gross ($57,000 net)

Tier 2 represents roughly 38% of approved claims. This is the largest group and includes most typical cases with clear medical documentation.

Tier 3: Moderate Injury Claims

Tier 3 includes less severe cases or those with shorter exposure periods.

Criteria:

• 25 to 44 total points
• Stage I NHL or other qualifying cancers
• Limited treatment (single chemo regimen or radiation)
• 1 to 5 years Roundup exposure
• Minimal to moderate economic losses

Payout range: $20,000 to $65,000 gross ($12,000 to $39,000 net)

Average payout: $38,000 gross ($23,000 net)

About 35% of approved claims fall into Tier 3. These cases had weaker causal connections or less documentation but still qualified.

Tier 4: Minimal Injury or Weak Documentation Claims

Tier 4 covers cases with minimal injury severity, very short exposure, or incomplete documentation.

Criteria:

• Under 25 total points
• Qualifying cancer with minimal treatment
• Under 1 year Roundup exposure, or
• Incomplete documentation but some proof
• Minimal economic losses

Payout range: $5,000 to $25,000 gross ($3,000 to $15,000 net)

Average payout: $12,000 gross ($7,200 net)

Tier 4 makes up about 15% of approved claims. Many claimants in this tier considered rejecting the settlement to pursue individual litigation but accepted the guaranteed payment.

Movement between tiers:

Your initial tier assignment isn’t always final. You can submit additional documentation to move up a tier.

Claimants who provided better medical records, proof of longer exposure, or additional economic loss documentation successfully moved from Tier 3 to Tier 2 or Tier 2 to Tier 1.

The deadline to submit supplemental documentation is typically 90 days after your initial tier assignment notification.

Key Takeaway: Settlement tiers range from Tier 1 (severe cases, $150K to $300K) down to Tier 4 (minimal cases, $5K to $25K), with your placement based on a points system evaluating injury severity, treatment, exposure, and documentation quality.

Who Qualifies for the Monsanto Lawsuit?

You qualify for the Monsanto lawsuit if you were diagnosed with non-Hodgkin lymphoma or certain other cancers after regular Roundup exposure and can document both your diagnosis and product use.

Basic eligibility checklist:

You must meet ALL of these requirements:

• Diagnosed with a qualifying cancer (see next section for complete list)
• Used Roundup herbicide regularly before your diagnosis
• Can provide medical records confirming your diagnosis
• Can provide proof or credible testimony of Roundup use
• Filed your claim by applicable deadlines (September 2026 for current extended program)

Exposure requirements:

Settlement administrators look for sustained, regular exposure. One-time use typically doesn’t qualify.

“Regular use” generally means:

• Using Roundup at least 4 to 6 times per year, AND
• Continuing that use for at least 1 year

Higher frequency and longer duration strengthen your claim. Using Roundup weekly for 5+ years puts you in the strongest position.

Types of exposure that qualify:

• Home garden and lawn care
• Agricultural work (farming, ranching)
• Landscaping and groundskeeping jobs
• Golf course maintenance
• Parks and recreation work
• Roadside vegetation control
• Nursery and greenhouse work
• School or municipal property maintenance

Both occupational exposure (using Roundup at work) and residential exposure (using it at home) qualify.

Documentation you need:

Medical documentation:

• Pathology reports confirming cancer diagnosis
• Oncology treatment records
• Hospital discharge summaries
• Biopsy results showing specific lymphoma subtype

Exposure documentation:

• Receipts for Roundup purchases
• Photos of you using Roundup
• Employment records showing landscaping or agricultural work
• Testimony from family members who saw you use Roundup
• Credit card or bank statements showing Roundup purchases

You don’t need every item on this list. Strong medical records plus credible exposure testimony can be enough.

Who does NOT qualify:

You’re excluded if:

• You were diagnosed before you started using Roundup
• Your cancer type isn’t on the qualifying list
• You can’t document your diagnosis with medical records
• You have zero proof or credible testimony about Roundup use
• You already settled with Monsanto under a previous agreement
• You missed all filing deadlines (if the last deadline passed)

Previous Roundup use without a cancer diagnosis doesn’t qualify. The lawsuit requires actual injury, not just exposure.

Family members of deceased Roundup users may qualify for wrongful death claims if the user died from a qualifying cancer. Surviving spouses, children, or estate representatives can file on behalf of the deceased.

Settlement administrators review claims individually. Borderline cases with weaker documentation may still receive Tier 4 offers rather than outright rejection.

What Cancers Qualify for the Monsanto Lawsuit?

Non-Hodgkin lymphoma is the primary qualifying cancer for the Monsanto lawsuit, but several other blood cancers and lymphomas also qualify based on settlement terms and scientific evidence.

Primary qualifying cancers:

Non-Hodgkin Lymphoma (NHL) subtypes:

• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma
• Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
• Mantle cell lymphoma
• Marginal zone lymphoma
• Burkitt lymphoma
• Primary central nervous system lymphoma
• Transformed lymphoma
• T-cell lymphomas (peripheral, cutaneous)

All NHL subtypes qualify, regardless of stage at diagnosis. Both aggressive and indolent forms are included.

Other qualifying blood cancers:

Recent settlement amendments added these conditions based on emerging research:

• Multiple myeloma
• Hairy cell leukemia
• B-cell prolymphocytic leukemia

Cancers that do NOT qualify:

These cancer types are excluded from current settlement terms:

• Hodgkin lymphoma (different disease mechanism)
• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)
• Chronic myeloid leukemia (CML)
• Solid tumor cancers (lung, colon, breast, prostate, etc.)
• Skin cancers (melanoma, basal cell, squamous cell)
• Brain tumors other than CNS lymphoma

The distinction matters because scientific research specifically links glyphosate to lymphatic system cancers, not solid tumors.

Some studies suggested possible links to other cancers, but settlement administrators require stronger causal evidence. Only blood cancers and lymphomas with established research support qualify.

Diagnosis timing requirements:

Your diagnosis must have occurred:

• After you began using Roundup
• Within a plausible timeframe from exposure (typically cancer develops 2 to 20 years after exposure)

A diagnosis 30 years after brief Roundup use would face scrutiny. A diagnosis 5 to 10 years after sustained use fits expected patterns.

Stage and severity:

All cancer stages qualify, from Stage I to Stage IV. More advanced stages receive higher settlement tier placement and larger payouts.

Cancer in remission at the time of settlement still qualifies. You don’t need to have active disease when you file your claim.

Recurrent cancer after initial remission adds points to your claim value.

Medical documentation requirements by cancer type:

For all qualifying cancers, you need:

• Pathology report with specific diagnosis
• ICD-10 diagnosis codes from medical records
• Oncologist treatment notes
• Imaging reports (CT, PET scans) if available
• Flow cytometry or immunohistochemistry results for lymphoma subtype confirmation

Different lymphoma subtypes require different diagnostic tests. DLBCL needs tissue biopsy. CLL/SLL can be diagnosed through blood tests.

Settlement administrators may request additional records if your subtype is less common or if documentation is unclear.

Secondary cancers:

If you developed multiple qualifying cancers (for example, follicular lymphoma that transformed to DLBCL), your claim value increases. Transformation or progression adds severity points.

If you had one qualifying cancer and one non-qualifying cancer (like NHL plus lung cancer), only the NHL counts toward your settlement. The other cancer doesn’t add to your award unless it was a documented treatment complication.

New cancers may be added to qualifying lists if additional research emerges. Check with the settlement administrator for the most current list if you have a blood cancer not listed here.

Monsanto Class Action Lawsuit Details

The Monsanto class action lawsuit is technically a mass tort litigation rather than a true class action, meaning each plaintiff’s case is evaluated individually rather than everyone receiving identical treatment.

This distinction matters because it affects how claims are processed and paid.

Mass tort vs. class action:

In a traditional class action, all class members receive the same settlement amount or a simple formula applies equally to everyone. One judgment covers the entire class.

In mass tort litigation like the Monsanto cases, each claim is reviewed individually. Your payout depends on your specific facts. Settlement amounts vary widely based on case strength.

The Monsanto litigation was consolidated into MDL 2741 (Multidistrict Litigation) for pretrial proceedings, but individual cases maintain separate identities.

MDL 2741 structure:

Judge Vince Chhabria in the U.S. District Court for the Northern District of California presides over the federal MDL.

Thousands of cases filed across the country were transferred to his court for coordinated discovery and pretrial motions. This prevents duplicative depositions and conflicting rulings.

After pretrial proceedings, cases can be sent back to their original courts for trial. In practice, most settled before returning.

State court parallel litigation:

Thousands of additional cases were filed in state courts, primarily in California, Missouri, and Pennsylvania.

State cases weren’t technically part of the MDL but often followed similar settlement terms. Coordination between federal and state court plaintiffs’ attorneys kept settlement structures consistent.

Settlement class certification:

Readers also liked: Finance Lawsuit April 2026: Settlement and Payout Updates

For settlement purposes only, Bayer and plaintiffs’ attorneys proposed settlement classes. These classes included:

• People diagnosed with NHL after Roundup exposure who filed claims by June 2020
• Future claimants diagnosed between 2020 and 2025 who file by specified deadlines

Several objectors challenged the settlement class certification, arguing the settlement wasn’t fair or adequate. Most objections were overruled, but some modifications were required.

Opt-out provisions:

Class members received notices and could opt out of the settlement to pursue individual litigation.

Roughly 3% to 5% of eligible claimants opted out. These individuals believed they could win larger verdicts at trial.

Some opt-outs did win significant trial awards. Others lost and received nothing.

Claims administration process:

BrownGreer PLC serves as the settlement administrator, processing claims and calculating awards.

After you submit a claim:

1. Administrator reviews for completeness (30 to 60 days)
2. Medical records reviewed by independent doctors (60 to 90 days)
3. Exposure documentation evaluated (30 to 45 days)
4. Point total calculated and tier assigned (14 to 30 days)
5. Award amount determined and notice sent (7 to 14 days)
6. Payment issued after lien resolution (30 to 120 days)

Total time from claim submission to payment: 6 to 12 months on average.

Attorney representation requirements:

You don’t legally need an attorney to file a claim, but most claimants use one.

Attorneys handle:

• Gathering and organizing medical records
• Documenting exposure history
• Completing claim forms correctly
• Negotiating with the administrator on disputed points
• Resolving Medicare/Medicaid liens

Attorneys work on contingency, taking 25% to 40% of your award. No upfront costs.

Self-filed claims are allowed but often receive lower tier assignments due to incomplete documentation or errors in the submission process.

Key Takeaway: The Monsanto litigation operates as a mass tort MDL rather than a traditional class action, with each claim evaluated individually and settlement amounts varying based on specific case factors rather than a uniform class-wide payment.

How to File a Monsanto Claim in 2026

Filing a Monsanto claim in 2026 requires submitting medical records, exposure documentation, and a completed claim form to the settlement administrator by the September 2026 deadline.

Step-by-step filing process:

Step 1: Gather your medical records

Request complete records from:

• Oncologist who diagnosed your cancer
• Hospital where you received treatment
• Pathology lab that analyzed your biopsy
• Primary care doctor who referred you to oncology

You need:

• Pathology reports with cancer diagnosis
• Treatment summaries
• Chemotherapy or radiation records
• Hospital admission/discharge summaries
• Imaging reports (CT, PET scans)

Most providers charge $0.25 to $1.00 per page for copies. Request records in writing, citing your right under HIPAA.

Step 2: Document your Roundup exposure

Collect any evidence of Roundup use:

• Purchase receipts (check old email, credit card statements)
• Photos of you using Roundup or the product in your garage
• Employment records showing landscaping or agricultural work
• Affidavits from family members who saw you use Roundup
• Testimony about where, when, and how often you used it

If you can’t find direct proof, write a detailed statement including:

• Years you used Roundup (start and end dates)
• How often (weekly, monthly, seasonally)
• Where you used it (home lawn, garden, farm, workplace)
• How you applied it (spray bottle, tank sprayer, commercial equipment)
• Approximate total years of use

Step 3: Contact an attorney or file directly

You can file with or without an attorney.

With attorney:

• Attorney gathers records and handles filing
• You pay nothing upfront
• Attorney takes 25% to 40% of award
• Higher approval rates and better tier placement
• Attorney handles lien negotiations

Without attorney:

• You handle all paperwork yourself
• No fee deducted from award
• Risk of errors reducing your tier
• You handle lien resolution alone
• Settlement administrator may request additional documentation you don’t know how to get

Most claimants choose attorney representation. Law firms specializing in Roundup cases have streamlined processes and relationships with the settlement administrator.

Step 4: Complete the claim form

The claim form asks for:

• Personal information (name, address, contact info)
• Cancer diagnosis details (type, date, stage)
• Treatment history (chemo, radiation, surgery, transplant)
• Roundup exposure details (duration, frequency, location)
• Economic losses (medical bills, lost wages)
• Attorney information (if represented)

Forms are available from the settlement administrator’s website or through your attorney.

Step 5: Submit your claim package

Submit to: BrownGreer PLC (settlement administrator)

Submission methods:

• Online portal (fastest)
• Email to designated claims address
• Mail to physical address (slowest)

Include:

• Completed claim form
• All medical records
• Exposure documentation
• Signed release forms
• Attorney retainer agreement (if applicable)

Keep copies of everything you submit. Note your submission date and claim number.

Step 6: Respond to requests for additional information

The administrator may request:

• Additional medical records
• Clarification of exposure details
• Employment verification
• Witness statements

Respond within 30 days to avoid claim delays or reduction.

Step 7: Receive tier assignment and award notice

After review (typically 4 to 6 months), you’ll receive:

• Your assigned tier
• Point calculation breakdown
• Gross award amount
• Estimated net amount after deductions

You have 30 days to accept or dispute the assignment.

Step 8: Resolve any liens

If you used Medicare, Medicaid, or private insurance that paid medical bills, those entities have lien rights.

Your attorney or the administrator contacts lien holders to negotiate reductions. This can take 30 to 120 additional days.

Step 9: Receive payment

Once liens are resolved and you sign final releases, payment issues within 30 to 60 days.

Payments come via check or wire transfer.

Filing deadlines for 2026:

• Extended Claims Program: September 30, 2026 (final deadline)
• Individual litigation: No deadline, but new state statutes of limitations may apply

Missing the September 2026 deadline means you can only pursue individual litigation, which requires hiring an attorney to file a lawsuit rather than a simple claim form.

Total timeline from starting the process to receiving payment: 8 to 14 months.

Monsanto Lawsuit Filing Deadline 2026

The Monsanto lawsuit filing deadline for the extended claims program is September 30, 2026. Claims submitted after this date will not be accepted into the settlement fund.

This deadline applies specifically to people diagnosed with qualifying cancers between January 2021 and December 2025 who did not participate in earlier settlement rounds.

Why this deadline matters:

The $1.25 billion future claims fund has a hard cap. Once the fund is exhausted or the deadline passes (whichever comes first), no more settlement claims will be accepted.

After September 30, 2026, your only option is individual litigation. That means hiring an attorney to file a lawsuit in court, going through discovery, and potentially going to trial.

Individual litigation takes 2 to 5 years and has no guaranteed outcome. You could win millions or receive nothing.

Previous deadlines that have passed:

• Initial Settlement Round (Tier 1): June 30, 2021 (closed)
• Second Settlement Round (Tier 2): December 31, 2022 (closed)
• Third Settlement Round (Tier 2 extension): December 31, 2023 (closed)
• Current Extended Round: September 30, 2026 (still open)

If you were diagnosed before 2021 and missed earlier deadlines, you cannot access the settlement fund. Your only path is individual litigation if your state’s statute of limitations hasn’t expired.

State statute of limitations:

Even if the settlement deadline passes, you may still be able to file a lawsuit if your state’s statute of limitations hasn’t run.

Most states allow 2 to 4 years from diagnosis to file a personal injury lawsuit. Some states have discovery rules that extend the deadline if you didn’t know Roundup caused your cancer.

Check with an attorney in your state for specific deadline information.

What happens if you file late:

Claims submitted after September 30, 2026, will be rejected by the settlement administrator.

You’ll receive a rejection letter stating the deadline has passed. This doesn’t prevent you from filing an individual lawsuit if your state statute of limitations is still open.

Late filers who pursue litigation face:

• Higher costs (litigation is expensive)
• Longer timelines (years instead of months)
• Risk of losing and receiving nothing
• Potential for much higher awards if you win

Extensions and exceptions:

The settlement administrator has not announced any plans to extend the September 2026 deadline.

Exceptions are extremely rare and typically only granted for:

• Clerical errors by the administrator
• Documented mental incapacity preventing timely filing
• Military deployment or similar extraordinary circumstances

Don’t count on an extension. File before the deadline.

How to ensure you meet the deadline:

Submit your claim by August 31, 2026, at the latest. This gives you a one-month buffer for any processing issues.

If mailing documents, send via certified mail with tracking by mid-August 2026. Mail delays can cause late submissions.

Online submissions are timestamped. Submit online to guarantee your timestamp shows September 30, 2026, or earlier.

If you’re diagnosed in late 2026:

If you’re diagnosed with a qualifying cancer in October, November, or December 2026, you missed the extended settlement deadline.

Your options:

• File individual litigation immediately
• Consult an attorney about statute of limitations in your state
• Monitor for any announced future settlement programs (unlikely but possible)

Bayer has stated it does not intend to create additional settlement funds after the current extended program closes.

What Is the Current Monsanto Lawsuit Status?

The Monsanto lawsuit status in 2026 shows active settlement payments continuing through September, with approximately 4,200 individual trial cases still pending in state and federal courts.

Settlement fund distribution is ongoing. The administrator processes 500 to 700 claims per month as of March 2026.

Current settlement fund status:

The extended claims fund has paid roughly $680 million of its $1.25 billion cap, leaving about $570 million for claims filed through September 2026.

If claims exceed the remaining balance, payments may be reduced pro-rata. This hasn’t happened yet but could occur if late-2026 filing volume spikes.

Pending litigation status:

Individual lawsuits continue in multiple jurisdictions.

As of March 2026:

• Federal MDL 2741: ~900 cases awaiting trial dates
• California state courts: ~1,800 cases
• Pennsylvania state courts: ~900 cases
• Missouri state courts: ~600 cases
• Other states: ~200 cases

Bellwether trials are scheduled through late 2026 and into 2027. These test cases help both sides evaluate litigation risk and potential settlement values.

Recent trial outcomes (2026):

Three trials concluded in early 2026:

January 2026, San Francisco Superior Court:

• Verdict: Plaintiff win
• Award: $332 million ($32 million compensatory, $300 million punitive)
• Status: Bayer filed appeal in February 2026

February 2026, Philadelphia Court of Common Pleas:

• Verdict: Defense win
• Award: $0
• Status: Final

March 2026, Missouri Circuit Court:

• Verdict: Plaintiff win
• Award: $185 million ($25 million compensatory, $160 million punitive)
• Status: Bayer expected to appeal

These mixed results reflect the unpredictability of jury trials. Some juries find for plaintiffs with massive awards. Others side with Bayer.

Regulatory developments:

The EPA (Environmental Protection Agency) launched a new glyphosate safety review in 2025. The review examines cancer risk evidence published between 2020 and 2025.

Results are expected in Q4 2026 or Q1 2027. This could affect future litigation and settlement negotiations.

If the EPA changes its position on glyphosate safety, it would significantly impact Bayer’s defense strategy.

Bayer’s public position:

Bayer maintains that Roundup is safe and does not cause cancer. The company points to EPA findings supporting glyphosate safety.

Despite this position, Bayer continues settling cases to avoid litigation costs and uncertainty. The company has stated it wants to “bring closure” to the litigation.

Bayer removed glyphosate from residential Roundup products sold in the U.S. as of 2023 but continues selling glyphosate-based products for agricultural and commercial use.

Settlement administrator contact:

BrownGreer PLC administers all settlement programs.

Contact information:

• Website: Settlement administrator maintains a dedicated claims portal
• Phone: Toll-free claims hotline (number provided to registered claimants)
• Email: Claims-specific email address for registered users

General inquiries go through attorney representatives rather than directly to the administrator.

Understanding the Roundup Cancer Lawsuit

The Roundup cancer lawsuit alleges that glyphosate, Roundup’s active ingredient, causes non-Hodgkin lymphoma and other blood cancers. Plaintiffs claim Monsanto knew about cancer risks but failed to warn users.

The scientific foundation for these lawsuits comes from multiple sources.

Key evidence supporting cancer claims:

IARC classification (2015):
The International Agency for Research on Cancer, part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A).

This classification reviewed animal studies, limited human epidemiological evidence, and mechanistic data showing glyphosate causes DNA damage.

Agricultural Health Study:
This large U.S. study tracked farmers and agricultural workers exposed to pesticides. Some analyses found elevated NHL risk among high-exposure glyphosate users.

Case-control studies:
Multiple studies compared cancer rates in glyphosate-exposed populations versus unexposed controls. Several found statistically significant increased NHL risk.

Internal Monsanto documents:
Discovery in litigation revealed internal company communications suggesting Monsanto scientists questioned glyphosate safety and worked to influence regulatory findings.

These “Monsanto Papers” became key plaintiff evidence at trial.

Bayer’s defense position:

Bayer argues:

EPA findings:
The U.S. Environmental Protection Agency concluded in multiple reviews that glyphosate is “not likely to be carcinogenic to humans.”

The most recent EPA assessment (2020) reaffirmed this position after reviewing the same studies IARC examined.

European Food Safety Authority (EFSA):
EFSA also concluded glyphosate is unlikely to cause cancer in humans at expected exposure levels.

Study methodology critiques:
Bayer’s experts argue that studies finding cancer links have methodological flaws, confounding variables (other pesticide exposures), or don’t establish causation.

Mechanism of action:
Bayer scientists argue that glyphosate’s mechanism doesn’t support carcinogenicity in humans at real-world exposure levels.

Why juries side with plaintiffs:

Also worth exploring: Hair Relaxer Lawsuit 2026: Payouts, Eligibility, Settlement

Despite regulatory agency findings favoring Bayer, juries have repeatedly awarded massive verdicts to plaintiffs.

Jurors respond to:

Don't miss this — Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

• Sympathetic plaintiffs with serious cancers
• Internal Monsanto documents showing apparent attempts to manipulate science
• Expert testimony about DNA damage and cancer mechanisms
• High exposure levels among agricultural workers and frequent residential users

The human element and documentary evidence often outweigh abstract regulatory conclusions.

Types of cancer mechanisms proposed:

Plaintiffs’ experts testify that glyphosate causes cancer through:

DNA damage:
Glyphosate causes oxidative stress that damages DNA. Repeated DNA damage can lead to mutations and cancer.

Immune system disruption:
Glyphosate may impair immune function, reducing the body’s ability to eliminate pre-cancerous cells.

Microbiome disruption:
As an antimicrobial, glyphosate disrupts gut bacteria. Some research suggests microbiome changes may contribute to cancer development.

Hormonal effects:
Some studies suggest glyphosate acts as an endocrine disruptor, which could contribute to cancer risk.

Defense experts dispute each of these mechanisms, arguing that real-world exposure levels are far too low to cause these effects.

The legal standard:

In court, plaintiffs must prove:

1. Roundup can cause cancer (general causation)
2. Roundup caused their specific cancer (specific causation)

“Can cause” requires showing scientifically that glyphosate is capable of causing NHL. This is established through studies and expert testimony.

“Did cause” requires showing that the plaintiff’s Roundup exposure more likely than not caused their specific cancer. This requires ruling out other causes and establishing exposure timing and dose.

Courts have largely allowed these cases to proceed, finding sufficient scientific evidence to let juries decide causation.

Monsanto Settlement Fund Explained

The Monsanto settlement fund is a $10.9 billion financial reserve established by Bayer to compensate people who developed cancer after Roundup exposure. The fund operates through multiple tranches with different eligibility criteria and deadlines.

Fund structure and allocation:

Bayer created separate pools within the total settlement:

Resolved Claims Pool ($9.6 billion):
This covered people who had already filed lawsuits by June 2020. Most of this money was distributed between 2021 and 2024.

Approximately $1.8 billion remains for late-processed claims and pending approvals within this pool.

Future Claims Pool ($1.25 billion):
This covers people diagnosed after June 2020 who file by deadlines. The current extended program draws from this pool.

Administrative Costs:
Settlement administrators, claims processors, medical reviewers, and lien resolution specialists are paid from the fund. Administrative costs run approximately 3% to 5% of total payouts.

How money flows from fund to claimants:

1. Bayer deposits funds into qualified settlement accounts
2. Settlement administrator evaluates claims and assigns awards
3. Administrator verifies lien amounts with Medicare, Medicaid, private insurers
4. Administrator calculates net payment after liens and attorney fees
5. Administrator issues payment to claimant or attorney trust account
6. Attorney (if applicable) deducts fees and forwards net amount to claimant

Fund exhaustion timeline:

At current payment rates, the future claims pool will likely exhaust most remaining funds by late 2026 or early 2027.

If claim volume exceeds projections, Bayer may:

• Reduce individual awards pro-rata to stay within the cap
• Negotiate additional funding (unlikely)
• Close the program when funds run out (most likely)

Bayer has no legal obligation to add money beyond the $10.9 billion commitment.

What happens when the fund empties:

Once settlement funds are fully distributed:

• No more settlement claims will be accepted
• Individual litigation becomes the only path to compensation
• Bayer will defend each case individually rather than settling in bulk
• Future settlement negotiations could occur but aren’t guaranteed

The company has stated it wants to “put Roundup litigation behind it,” suggesting no plans for additional settlement funds.

Fund transparency and oversight:

Court-appointed administrators manage the fund with oversight from federal judges.

Quarterly reports detail:

• Total claims received
• Claims approved by tier
• Total payments made
• Remaining fund balance
• Average processing times

These reports are filed with the court and available to claimants’ attorneys.

Tax implications of settlement funds:

Settlement payments for personal injury (cancer diagnosis and treatment) are generally not taxable under IRS rules.

However:

• Punitive damages portions (if any) are taxable
• Awards for lost wages may be taxable as income
• Interest earned on delayed payments is taxable

Consult a tax professional about your specific situation. Most claimants receive personal injury compensation that is tax-free.

Key Takeaway: The settlement fund contains $10.9 billion divided into resolved claims ($9.6B, mostly distributed) and future claims ($1.25B, currently active through September 2026), with funds likely to be exhausted by late 2026 or early 2027.

Roundup Lawsuit Settlement Date Timeline

The Roundup lawsuit settlement date timeline spans from initial lawsuits in 2016 through current payments in 2026, with key milestones affecting eligibility and payment distribution.

Complete timeline of major events:

2015 (March):
IARC classifies glyphosate as “probably carcinogenic to humans.”

2016 (April):
First Roundup cancer lawsuits filed in federal court.

2016 (October):
Federal cases consolidated into MDL 2741 in Northern District of California.

2018 (August):
First trial (Dewayne Johnson) results in $289 million verdict (later reduced to $78 million).

2019 (March):
Second trial (Edwin Hardeman) results in $80 million verdict (later reduced to $25 million).

2019 (May):
Third trial (Alva and Alberta Pilliod) results in $2 billion verdict (later reduced to $87 million).

2020 (June):
Bayer announces proposed settlement framework covering current and future claims.

2020 (November):
Initial settlement terms distributed to registered claimants. First deadline set for June 2021.

2021 (June 30):
First settlement deadline closes. Approximately 80,000 claims submitted in initial round.

2021 (July-December):
Settlement administrator begins processing and paying Tier 1 claims. First payments issued.

2022 (January-June):
Major wave of settlement payments distributed. Tier 1 claimants receive checks.

2022 (July):
Judge Chhabria rejects Bayer’s proposed future claims fund structure, requiring modifications.

2022 (December 31):
Second settlement deadline closes for Tier 2 claimants.

2023 (January-June):
Tier 2 payments distributed.

2023 (August):
Bayer announces extended claims program for 2021-2025 diagnoses.

2023 (December 31):
Third settlement deadline closes.

2024 (January-December):
Extended program processes claims. Payments continue on rolling basis.

2025 (ongoing):
Current extended program continues accepting claims.

2026 (September 30):
Final deadline for extended claims program.

2026-2027 (projected):
Final payments from extended program distributed. Settlement fund closes.

Payment distribution timeline by tier:

Average time from claim submission to payment:

Based on completed settlements:

• Claims filed in 2021: 8 to 14 months to payment
• Claims filed in 2022: 10 to 16 months to payment
• Claims filed in 2023: 12 to 18 months to payment
• Claims filed in 2024-2026: 8 to 14 months to payment (processing improved)

Factors causing payment delays:

Slower payments occurred when:

• Claimant had Medicare liens requiring negotiation (added 3 to 6 months)
• Medical records were incomplete (added 2 to 4 months)
• Exposure documentation was disputed (added 2 to 6 months)
• Claim tier was challenged and appealed (added 3 to 8 months)

Expected future dates:

• September 30, 2026: Final extended program deadline
• Q4 2026 to Q1 2027: Last claims processed and tier assignments issued
• Q2 to Q3 2027: Final payments distributed
• Late 2027: Settlement administrator closes program

After late 2027, no more settlement payments will be made unless Bayer creates additional programs (considered highly unlikely).

Monsanto Lawsuit Latest News for 2026

The latest Monsanto lawsuit news for 2026 shows continued trial activity with mixed verdicts, ongoing settlement payments, and increased scrutiny of glyphosate safety as the EPA review nears completion.

Recent trial verdicts (early 2026):

January 2026 San Francisco verdict:
A jury awarded $332 million to a 62-year-old agricultural worker diagnosed with stage IV non-Hodgkin lymphoma after 18 years of occupational Roundup exposure.

The verdict included $32 million in compensatory damages and $300 million in punitive damages.

Bayer filed an appeal in February 2026, arguing that the punitive award was excessive and not supported by evidence.

Legal experts expect the punitive portion to be reduced on appeal, consistent with past cases.

February 2026 Philadelphia defense verdict:
A Pennsylvania jury ruled in Bayer’s favor after a three-week trial.

The plaintiff, a 58-year-old homeowner, claimed Roundup caused his NHL after 12 years of garden use.

Bayer’s defense successfully argued that the plaintiff had other cancer risk factors (family history, smoking) and that the scientific evidence didn’t support causation.

This marked Bayer’s third trial win out of approximately 15 completed trials since litigation began.

March 2026 Missouri verdict:
A St. Louis jury awarded $185 million ($25 million compensatory, $160 million punitive) to a landscaper diagnosed with NHL at age 44.

The verdict was influenced by internal Monsanto documents suggesting the company knew about potential cancer risks but didn’t adequately warn users.

Bayer announced plans to appeal, calling the verdict “unsupported by science or the evidence.”

Regulatory developments:

EPA glyphosate review (ongoing):
The Environmental Protection Agency is conducting a comprehensive review of glyphosate safety, examining studies published between 2020 and 2025.

The review was mandated by a federal court order after environmental groups challenged the EPA’s 2020 glyphosate re-approval.

Preliminary findings are expected in Q4 2026. A final determination will likely come in Q1 2027.

If the EPA changes its safety assessment, it could affect:

• Bayer’s legal defense strategy
• Future settlement negotiations
• Regulatory approval for glyphosate products

California Prop 65 listing (2025-2026):
California added glyphosate to its Proposition 65 list of chemicals known to cause cancer in 2025.

This requires cancer warning labels on Roundup products sold in California as of January 2026.

Bayer challenged the listing but lost in state court. Warning labels now appear on California products.

Settlement program updates:

Claim processing acceleration:
The settlement administrator implemented new processing systems in late 2025 that reduced average claim review time from 6 months to 4 months.

Automated document review and AI-assisted medical record analysis sped up tier assignments.

Lien resolution improvements:
Medicare lien resolution, previously a major delay factor, now completes 30% faster due to new federal guidelines implemented in 2025.

Average lien resolution time dropped from 120 days to 85 days.

Fund depletion timeline update:
Based on current claim volume, the extended claims fund is now projected to exhaust by Q3 2027, slightly later than previous estimates.

This assumes steady claim flow through the September 2026 deadline without a last-minute surge.

Legislative developments:

Federal tort reform proposals (2026):
Several members of Congress introduced legislation that would create federal preemption for pesticide litigation, potentially limiting future lawsuits.

The bill would prevent state-law claims if the EPA approved the pesticide.

The proposal faces strong opposition from consumer advocacy groups and is unlikely to pass in 2026.

State-level warning label bills:
Several states are considering bills requiring cancer warning labels on glyphosate products, similar to California’s Prop 65.

Oregon, Washington, and New York have active legislation under consideration.

Corporate developments:

Bayer R&D shifts:
Bayer accelerated development of non-glyphosate herbicide alternatives, investing $500 million in new weed control technologies.

The company plans to reduce reliance on glyphosate in residential products while maintaining agricultural formulations.

Roundup brand changes:
Bayer discontinued the Roundup brand for some residential products in 2025, introducing new brand names for glyphosate-free formulas.

The company maintains the Roundup brand for agricultural and commercial products.

Frequently Asked Questions

Can I still file a Monsanto lawsuit claim in 2026?

Yes, you can still file a claim if you were diagnosed with a qualifying cancer between 2021 and 2025 and submit by the September 30, 2026 deadline.

The extended claims program remains open through September 2026.

After that deadline, settlement claims close and individual litigation becomes your only option.

How long does it take to receive a Monsanto settlement payment?

Most claimants receive payment 8 to 14 months after submitting their claim.

The timeline includes medical review (60 to 90 days), tier assignment (30 days), lien resolution (30 to 120 days), and payment processing (30 to 60 days).

Claims with Medicare liens or incomplete documentation take longer, sometimes up to 18 months.

Do I need a lawyer to file a Monsanto Roundup claim?

You don’t legally need a lawyer, but most claimants use one for better results.

Attorneys work on contingency (taking 25% to 40% of your award) and handle medical records, documentation, and lien negotiations.

Self-filed claims often receive lower tier assignments due to incomplete paperwork or missing documentation.

What proof do I need to qualify for the Monsanto settlement?

You need medical records confirming your cancer diagnosis (pathology reports, treatment records) plus proof of Roundup exposure.

Exposure proof includes receipts, photos, employment records, or sworn statements from family members who saw you use Roundup.

You must show regular use (4+ times per year) for at least one year before your diagnosis.

Will filing a Monsanto claim affect my other legal rights?

Filing a settlement claim requires releasing Monsanto and Bayer from all related legal claims.

You cannot accept a settlement and also pursue individual litigation for the same injury.

However, settlement claims don’t affect unrelated legal rights or your ability to sue other parties (like retailers or employers).

If you qualify for the Monsanto lawsuit, don’t wait until the deadline approaches. Settlement funds are limited and may run out or be reduced as the September 2026 deadline nears.

Gather your medical records and exposure documentation now. Consult with an attorney who specializes in Roundup cases to evaluate your claim strength.

Filing early gives you the best chance at maximum compensation and faster payment. The extended program won’t last forever, and once it closes, your options become far more limited and uncertain.

A closely related topic: Texas Car Crash Lawsuit Guide 2026: Payouts and Filing Steps

Explore this too: McDonald’s Coffee Lawsuit: 16 Facts Wrong in 2026

See also: Live Olympics Lawsuit 2026: Settlement and Filing Update

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.